# **Data Changes for the CCDD APRIL Release Candidate 2023**

## **Based on the QA Release Generation** 20230403

|  |  |
| --- | --- |
| Data entered by | A Raghuveer |
| Data checked by | J Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8001695 | antipyrine and benzocaine |
| 8001190 | diphenhydramine and phenylephrine |
| 8001194 | elbasvir and grazoprevir |
| 8001154 | peramivir |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9004837 | antipyrine 54 mg per mL and benzocaine 14 mg per mL otic drops |
| 9005559 | diphenhydramine hydrochloride 6.25 mg per 5 mL and phenylephrine hydrochloride 2.5 mg per 5 mL syrup |
| 9005863 | elbasvir 50 mg and grazoprevir 100 mg oral tablet |
| 9006082 | empagliflozin 10 mg and linagliptin 5 mg oral tablet |
| 9013285 | eptifibatide 20 mg per 10 mL solution for injection vial |
| 9013197 | leuprolide acetate 5 mg per mL solution for injection 2.8 mL vial |
| 9000943 | oxybutynin chloride 10 mg prolonged-release oral tablet |
| 9012537 | peramivir 200 mg per 20 mL solution for injection vial |
| 9004772 | white petrolatum 38 % and zinc oxide 40 % cutaneous ointment |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 83797 | 2352710 | AMOXICILLIN (amoxicillin (amoxicillin trihydrate) 250 mg oral capsule) SANIS HEALTH INC | Dormant 2023.03.22 |
| 72854 | 2248502 | APO-QUINAPRIL (quinapril (quinapril hydrochloride) 40 mg oral tablet) APOTEX INC | Dormant 2023.01.07 |
| 75484 | 2269465 | ARICEPT RDT (donepezil hydrochloride 10 mg orodispersible tablet) PFIZER CANADA ULC | Canceled post-market Expiry 2023.03.31 |
| 81814 | 2332477 | AURALGAN (antipyrine 54 mg per mL and benzocaine 14 mg per mL otic drops) PALADIN LABS INC. | Canceled post-market Expiry 2023.03.31 |
| 67904 | 2243961 | DITROPAN XL (oxybutynin chloride 10 mg prolonged-release oral tablet) JANSSEN INC | Canceled post-market Expiry 2023.03.31 |
| 83796 | 2352702 | EXTRA STRENGTH DIAPER RASH OINTMENT (white petrolatum 38 % and zinc oxide 40 % cutaneous ointment) CRLS | Canceled post-market Expiry 2023.03.30 |
| 12218 | 401633 | FUROSEMIDE SPECIAL (furosemide 250 mg per 25 mL solution for injection vial) SANDOZ CANADA INCORPORATED | Dormant 2023.02.27 |
| 83566 | 2350459 | GLYBURIDE (glyburide 2.5 mg oral tablet) SANIS HEALTH INC | Dormant 2023.03.22 |
| 94707 | 2459752 | GLYXAMBI (empagliflozin 10 mg and linagliptin 5 mg oral tablet) BOEHRINGER INGELHEIM (CANADA) LTD LTEE | Canceled post-market 2023.04.01 |
| 63894 | 2240352 | INTEGRILIN (eptifibatide 20 mg per 10 mL solution for injection vial) MERCK CANADA INC | Canceled post-market Expiry 2023-04-03 |
| 89696 | 2412349 | JACK & JILL BEDTIME COUGH & COLD (diphenhydramine hydrochloride 6.25 mg per 5 mL and phenylephrine hydrochloride 2.5 mg per 5 mL syrup) THE BUCKLEY'S COMPANY | Canceled post-market |
| 7367 | 727695 | LUPRON (leuprolide acetate 5 mg per mL solution for injection 2.8 mL vial) ABBVIE CORPORATION | Canceled post-market Expiry 2023.03.30 |
| 93263 | 2447053 | MAR-MOXIFLOXACIN (moxifloxacin (moxifloxacin hydrochloride) 400 mg oral tablet) MARCAN PHARMACEUTICALS INC | Dormant 2023.02.19 |
| 93057 | 2445344 | PRIVA-CIPROFLOXACIN (ciprofloxacin (ciprofloxacin hydrochloride) 500 mg oral tablet) PHARMAPAR INC | Canceled post-market Expiry 2023.03.31 |
| 94760 | 2460319 | RAPIVAB (péramivir 200 mg par 20 mL solution injectable fiole) BIOCRYST PHARMACEUTICALS INC | Marketed in error changed to aprroved now |
| 71686 | 2247440 | SANDOZ BISOPROLOL (bisoprolol fumarate 10 mg oral tablet) SANDOZ CANADA INCORPORATED | Cancelled post-market 2023.03.07 |
| 71685 | 2247439 | SANDOZ BISOPROLOL (bisoprolol fumarate 5 mg oral tablet) SANDOZ CANADA INCORPORATED | Cancelled post-market 2023.03.07 |
| 70176 | 2246045 | SUSTIVA TABLETS (efavirenz 600 mg oral tablet) BRISTOL-MYERS SQUIBB CANADA | Canceled post-market Expiry 2023.03.31 |
| 76949 | 2283913 | VICKS DAYQUIL COUGH (dextromethorphan hydrobromide 5 mg per 5 mL syrup) PROCTER & GAMBLE INC | Canceled post-market Expiry 2023.03.31 |
| 93740 | 2451131 | ZEPATIER (elbasvir 50 mg and grazoprevir 100 mg oral tablet) MERCK CANADA INC | Canceled post-market Expiry 2023.03.09 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the DECEMBER 2022 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
|  | lidocaine 0.8 % cutaneous gel | 98886 | 02499118 | AFTER SUN GEL (lidocaine 0.8 % cutaneous gel) FRUIT OF THE EARTH, INC | STAY |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 2515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |